pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,175 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints785BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health73
therapy area
allOncology6110Rare Disease1467Cardiology1094Hematology1031Immunology1020Vaccines919Pulmonology
  • STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
    The drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer exceeded its expectations.
    STAT · 3mo ago↗ source
  • Erasca reports RAS cancer drug data after legal threat from Revolution
    After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown b…
    Endpoints · 3mo ago↗ source
  • STAT+: Dems say RFK Jr. has a pattern of failing to answer their questions
    Kennedy broke his pledge to share a controversial contract, highlighting Democrats' frustrations with the health secretary.
    STAT
← prev
page 85 of 87
next →
fda recalls48
fda medwatch41
fda press28
911
Psychiatry & CNS727
Ophthalmology425
Pain406
Endocrinology & Metabolism390
Infectious Disease362
· 3mo ago
↗ source
  • Revolution Medicines threatens to sue Erasca over patent, efficacy claims
    Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, Erasca said it had received a legal threat from Revolution Medicines' lawyers ove…
    Endpoints · 3mo ago↗ source
  • Trump administration warns against using federal dollars on fentanyl test strips
    The Trump administration underlines a “clear shift away from harm reduction and practices” that it says facilitates illegal drug use.
    STAT · 3mo ago↗ source
  • Utah doctors demand suspension of Doctronic AI program
    Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications. The startup, Doctronic, struck an ag…
    Endpoints · 3mo ago↗ source
  • Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next
    Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous…
    Endpoints · 3mo ago↗ source
  • Thermo Fisher sells microbiology biz; Ligand to buy XOMA
    Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of its specialt…
    Endpoints · 3mo ago↗ source
  • STAT+: An insider reveals the real goals of prior authorization
    Years ago, Archelle Georgiou helped squash prior auths at one of America's biggest health insurers.
    STAT · 3mo ago↗ source
  • Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
    Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…
    Endpoints · 3mo ago↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
    Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
    STAT · 3mo ago↗ source
  • What’s the true risk for eating disorders with GLP-1s?
    The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning Rounds
    STAT · 3mo ago↗ source
  • Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
    Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
    Endpoints · 3mo ago↗ source
  • Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial
    A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…
    Endpoints · 3mo ago↗ source
  • Intellia's in vivo CRISPR therapy first to succeed in Phase 3
    An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…
    Endpoints · 3mo ago↗ source
  • STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
    With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
    STAT · 3mo ago↗ source
  • Veradermics wins at growing hair with oral Rogaine in first key test as a public company
    Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair…
    Endpoints · 3mo ago↗ source
  • AI biotech Fathom raises $47M Series A, renames from Atommap
    In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafeng…
    Endpoints · 3mo ago↗ source
  • STAT+: Veradermics’ hair loss drug succeeds in late-stage trial
    The company is one of the most advanced players in the hair loss field, which has seen a surge of investor enthusiasm.
    STAT · 3mo ago↗ source
  • STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
    A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
    STAT · 3mo ago↗ source
  • STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
    FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat depression.
    STAT · 3mo ago↗ source
  • NIH-funded research lags in reporting sex differences, new study finds
    Fewer than half of papers published by NIH-funded researchers analyze or report their data by sex, a new study found.
    STAT · 3mo ago↗ source
  • Opinion: I’m a fourth-year med student, but I only learned one historical example of medical racism
    Modern randomized controlled trials often rely on marginalized populations abroad.
    STAT · 3mo ago↗ source
  • Opinion: Patients seeking mental health treatment are not commodities
    Legal agreements that directly shape access to care remain invisible to the very people whose lives they govern.
    STAT · 3mo ago↗ source